Hopp til hovedinnhold

Primærforebygging av hjerte- og karsykdommer

Sist oppdatert: Sist revidert:
Sist revidert av:

  • Artikkelen er basert på Nasjonale retningslinjer for individuell primærforebygging av hjerte- og karsykdommer - 2017 20
  1. Nilsen A, Hanssen TA, Lappegård KT, et al. Change in cardiovascular risk assessment tool and updated Norwegian guidelines for cardiovascular disease in primary prevention increase the population proportion at risk: the Tromsø Study 2015–2016. Open Heart 2021; 8: e001777. pmid:34462328 PubMed  
  2. Lindholt JS, Søgaard R, Rasmussen LM, et al. Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. N Engl J Med 2022; 387: 1385-94. pmid:36027560 PubMed  
  3. Madsen CM, Varbo A, Nordestgaard BG . Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: 2 prospective cohort studies. Eur Heart J 2017; 38: 2478-86. pmid:28419274 PubMed  
  4. Nanna MG, Navar AM, Wojdyla D, Peterson ED. The association between low-density lipoprotein cholesterol and incident atherosclerotic cardiovascular disease in older adults: Results from the National Institutes of Health pooled cohorts. J Am Geriatr Soc 2019; 67:2560-67. PMID: 31411740 PubMed  
  5. Raitakari O, Kartiosuo N, Pahkala K, et al. Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood. Circulation. 2023;147(1):23-31. PubMed  
  6. Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol 2022; 7: 250-256. pmid:34773460 PubMed  
  7. The Emergency Risk Factors Collaboration. Separate and combined association of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011; : doi: 10.1016/S0140-6736(11)60105-0. DOI  
  8. Jayedi A, Soltani S, Zargar MS, et al. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ 2020; 370: m3324. pmid:32967840 PubMed  
  9. Myint PK, Kwok CS, Luben RN. Body fat percentage, body mass index and waist-to-hip ratio as predictors of mortality and cardiovascular disease. Heart 2014. doi:10.1136/heartjnl-2014-305816 DOI  
  10. Ma Y, He FJ, Sun Q, et al. 24-hour urinary sodium and potassium excretion and cardiovascular risk. N Engl J Med 2021. PMID: 34767706 PubMed  
  11. Mirza Y, Prestgaard EE, Selmer R, et al. Tiårsprediksjon av hjerte- og karsykdom hos friske norske menn basert på NORRISK-2. Tidsskr Nor Legeforen 2020. doi:10.4045/tidsskr.20.0089 DOI  
  12. Debras C, Chazelas E, Sellem L, et al. CCBYNC Open access Research Artificial sweeteners and risk of cardiovascular diseases: results from the prospective NutriNet-Santé cohort. BMJ 2022; 378: e+71204. doi:10.1136/bmj-2022-071204 DOI  
  13. Biddinger KJ, Emdin CA, Haas ME, et al. Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease. JAMA Netw Open 2022; 5: e223849. doi:10.1001/jamanetworkopen.2022.3849 DOI  
  14. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2021; 42: 3227-3337. doi:10.1093/eurheartj/ehab484 DOI  
  15. Kessous R, Shoham-Vardi I, Pariente G, et al. Long-term maternal atherosclerotic morbidity in women with pre-eclampsia. Heart 2014. doi:10.1136/heartjnl-2014-306571 DOI  
  16. El Khoudary SR, Aggarwal B, Beckie TM et al.; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020 Dec 22;142(25):e506-e532. Epub 2020 Nov 30. PMID: 33251828 PubMed  
  17. Kakoly NS, Moran LJ, Teede HJ, Joham AE. Cardiometabolic risks in PCOS: a review of the current state of knowledge. Expert Rev Endocrinol Metab. 2019 Jan;14(1):23-33. Epub 2018 Dec 15. PMID: 30556433 PubMed  
  18. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929-934. PubMed  
  19. Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 2011; 124: 775. PubMed  
  20. Nasjonale retningslinjer for individuell primærforebygging av hjerte- og karsykdommer. Helsedirektoratet, 2017.
  21. Conrad N, Verbeke G, Molenbergs G, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 2022. doi:10.1016/S0140-6736(22)01349-6 DOI  
  22. Carr JJ, Jacobs DR, Terry JG, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol 2017. PMID: 28196265 PubMed  
  23. Peng AW, Dardari ZA, Blumenthal RS, et al. Very high coronary artery calcium (≥1000) and association with cardiovascular disease events, non–cardiovascular disease outcomes, and mortality: Results from MESA. Circulation 2021; 143:1571. PMID: 33650435 PubMed  
  24. Pedersen ER, Hovland S, Karaji I, et al. Coronary calcium score in the initial evaluation of suspected coronary artery disease. Heart 2023. pmid:36549683 PubMed  
  25. Kavousi M, Desai CS, Ayers C, et al. Prevalence and prognostic implications of coronary artery calcification in low-risk women: A meta-analysis. JAMA 2016. PMID: 27846641 PubMed  
  26. Lin JS, Evans CV, Johnson E, et al. Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018; 320: 281-97. pmid:29998301 PubMed  
  27. Bell KJ, White S, Hassan O, et al. Evaluation of the Incremental Value of a Coronary Artery Calcium Score Beyond Traditional Cardiovascular Risk Assessment A Systematic Review and Meta-analysis. JAMA Intern Med 2022. pmid:35467692 PubMed  
  28. Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet 2012; 379: 2053-62. PubMed  
  29. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012; 308: 796-803. Journal of the American Medical Association  
  30. Ganz P, Heidecker B, Hveem K, et al. Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. JAMA 2016; 315: 2532-41. doi:10.1001/jama.2016.5951 DOI  
  31. Groenendyk JW, Greenland P, Khan SS, et al. Incremental Value of Polygenic Risk Scores in Primary Prevention of Coronary Heart Disease A Review. JAMA Intern Med 2022. pmid:35994254 PubMed  
  32. Swaminathan S, Dehghan M, Raj JM, et al. Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: Prospective cohort study. BMJ 2021 Feb 3; 372:m4948. PMID: 33536317 PubMed  
  33. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk The STRENGTH Randomized Clinical Trial. JAMA 2020. doi:10.1001/jama.2020.22258 DOI  
  34. Rees K, Al-Khudairy L, Takeda A, et al. Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases. Cochrane Database Syst Rev. 2021 Feb 25;2:CD013501. doi: 10.1002/14651858.CD013501.pub2. DOI  
  35. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA 2022 Aug 23; 328:746-753. PMID: 35997723 PubMed  
  36. Legeforeningen. Gjør kloke valg. Norsk forening for allmennmedisin. Oppdatert 28.02.2020. Siden besøkt 11.02.2021 www.legeforeningen.no  
  37. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–88. PMID: 31504418 PubMed  
  38. Retterstøl K, Munkhaugen J, Ingul CB, et al. Lavere behandlingsmål for LDL-kolesterol bør innføres. Tidsskr Nor Legeforen 2021. doi:10.4045/tidsskr.20.0761 DOI  
  39. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol 2013. doi:10.1016/j.jacc.2013.11.002 DOI  
  40. NICE. NICE recommends wider use of statins to cut cardiovascular risk. BMJ 2023; 380: 89. doi:10.1136/bmj.p89 DOI  
  41. Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: Systematic review with pairwise, network, and dose-response meta-analyses. BMJ 2021 Jul 14; 374:n1537. PMID: 34261627 PubMed  
  42. US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA 2022; 327: 1577-84. doi:10.1001/jama.2022.4983 DOI  
  43. ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804988. PMID: 30146931 PubMed  
  44. McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018 Oct 18;379(16):1509-1518. doi: 10.1056/NEJMoa1805819. Epub 2018 Sep 16
  45. Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events A Systematic Review and Meta-analysis. JAMA 2019; 321: 277-87. pmid:30667501 PubMed  
  46. Joseph P, Roshandel G, Gao P, et alq. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021. pmid:34469765 PubMed  
  47. Udell JA, Zawi R, Bhatt DL, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013 Oct 23;310(16):1711-20. PubMed  
  48. Kim Y-E, Huh K, Park Y-J, et al. Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection. JAMA 2022; 328: 887-889. pmid:35867050 PubMed  
  49. Clarke R, Emberson J, Fletcher A, et al. Life expectancy in relation to cardiovascular risk factors: 38 year follow-up of 19 000 men in the Whitehall study. BMJ 2009; 339: b3513. BMJ (DOI)  
  50. Chiuve SE, Fung TT, Rexrode KM, et al. Adherence to a low-risk, healthy lifestyle and risk of suddeen cardiac death among women. JAMA 2011; 306: 62-9. Journal of the American Medical Association  
  51. Threapleton DE, Greenwood DC, Evans CEL, et al. Dietary fibre intake and risk of cardiovascular disease: Systematic review and meta-analysis. BMJ 2013; 347:f6879. doi.org/10.1136/bmj.f6879
  52. Dehghan M, Mente A, Rangarajan S, et al. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2018; 392: 2288-97. pmid:30217460 PubMed  
  53. Christoffersen M, Frikke-Schmidt R, Schnohr P, et al. Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in generel population. BMJ 2011; 343: d5497. BMJ (DOI)  
  54. Sesso HD, Christen WG, Bubes V, et al. Multivitamins in the Prevention of Cardiovascular Disease in Men: The Physicians` Health Study II Randomized Controlled Trial. JAMA 2012 Nov 7; 308(17): 1751-60. PubMed  
  55. Myung SK, Ju W, Cho B, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 346: f10. BMJ (DOI)  
  56. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018; 7: CD003177. PMID: 30019766 PubMed  
  57. Manson JE, Cook NR, Lee I-Min, et al. Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med 2018. pmid:30415637 PubMed  
  58. Khera AV, Emdin CA, Drake I, et al. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. N Engl J Med 2016, Dec; 375: 2349-2358. pmid:27959714 PubMed  
  59. Yusuf S, LonnE, Bosch J, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016. doi:10.1056/NEJMoa1600177 DOI  
  60. Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease published online ahead of print, 2020 Nov 13. N Engl J Med. 2020;10.1056/NEJMoa2028220. Pmid: 33186492 PubMed  
  61. Rothwell PM, Cook NR, Gaziano M, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018. pmid:30017552 PubMed  
  62. Lau FD, Giugliano RP. Lipoprotein(a) and its Significance in Cardiovascular Disease A Review. JAMA Cardiol 2022. doi:10.1001/jamacardio.2022.0987 DOI  
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL